HRS-8427 + Meropenem
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hospital-acquired Bacterial Pneumonia (HABP)
Conditions
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Trial Timeline
Apr 3, 2025 → Feb 1, 2026
NCT ID
NCT06841731About HRS-8427 + Meropenem
HRS-8427 + Meropenem is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Hospital-acquired Bacterial Pneumonia (HABP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06841731. Target conditions include Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP).
What happened to similar drugs?
1 of 2 similar drugs in Hospital-acquired Bacterial Pneumonia (HABP) were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06841731 | Phase 2 | Recruiting |
Competing Products
2 competing products in Hospital-acquired Bacterial Pneumonia (HABP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMI/REL FDC + PIP/TAZ FDC + Linezolid | Merck | Phase 3 | 40 |
| Zavicefta, Ceftazidime-Avibactam | Pfizer | Approved | 43 |